Back to News
Market Impact: 0.2
CytoDyn Announces CEO Transition As Board Appoints Hoffman; Lazaleri Steps Down
Source: Nasdaq
Management & GovernanceHealthcare & BiotechCompany Fundamentals
CytoDyn appointed Robert E. Hoffman CEO effective October 20, 2026. He succeeds Dr. Jacob Lalezari, who had held the role since November 2023; the announcement provided no additional details on the leadership transition.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas
- Anthropic May Spend $750 Billion on Computing Costs, WSJ Reports
- This Janus Henderson fund manager owns CoreWeave debt — here's why he's sticking with it
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect
- Fintool Alternatives After the Microsoft Acquisition